시장보고서
상품코드
1429509

세계의 암 면역치료제 시장 보고서(2024년)

Immuno-Oncology Drugs Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

암 면역치료제 시장 규모는 향후 몇 년동안 빠르게 성장할 것으로 예상됩니다. 2028년에는 13.5%의 연평균 복합 성장률(CAGR)로 1,750억 5,000만 달러 규모에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 암 면역학에 대한 투자 증가, 암 치료를 위한 면역치료제에 대한 관심 증가, 전략적 제휴를 통한 제품 혁신, 시장을 견인할 것으로 예상되는 노인 인구 증가에 기인합니다. 예측 기간 동안 주요 동향으로는 생체 이용률을 높이고 피하 경로와 관련된 부작용을 줄이기 위한 마이크로니들 주사제 기반 의약품의 개발이 포함됩니다. 기업들은 특정 환자 프로파일에 맞는 맞춤형 종양 치료제 개발에 대한 투자를 고려하고, 시장 점유율을 확대하고 제품 포트폴리오를 확장하기 위해 인수를 고려하고, 수익과 시장 점유율을 확대하기 위해 차세대 생물학적 제제 개발에 집중하고 우선순위를 부여하는 것이 바람직합니다. 암 치료를 위한 항체 약물 복합체 개발. 또한 R&D 비용 절감과 개발 시간 단축을 위한 AI 솔루션에 대한 투자, 새로운 종양 치료제 시험을 위한 3D 프린팅 장치 도입, 혁신과 카테고리 리더십을 위한 면역항암제 병용요법 탐색, CAR-T 요법 도입을 통한 혁신 및 카테고리 리더십 확보 등이 있습니다. 혁신과 카테고리 리더십을 확립하는 것이 중요합니다. 혁신과 카테고리 리더십을 확립하는 것이 권장되는 전략입니다.

암 면역치료제 시장의 성장은 전 세계 암 환자 증가로 인해 촉진될 것으로 예상됩니다. 특히 미국 암 협회는 2022년 1월 미국에서만 190만 명이 새로 암 진단을 받고 60만 9,360명이 암으로 사망할 것으로 예상된다고 발표해 문제의 심각성을 강조하고 있습니다. 폐암, 전립선암, 장암, 여성 유방암 등 전 세계적으로 가장 많이 발생하는 암은 전체 신규 암 발병의 43%를 차지합니다. 전 세계적으로 암 발병률이 증가함에 따라 향후 몇 년동안 암 면역치료제에 대한 수요가 급증할 것으로 예상됩니다.

의료비 지출 증가는 암 면역치료제 시장의 중요한 촉진요인으로 인식되고 있습니다. 의료 지출은 개인, 조직 또는 정부가 의료 관련 상품 및 서비스에 할당 한 총 재정 자원을 의미하며 암 면역 치료제의 개발, 접근성 등 이용에 중요한 결정 요인으로 Centers for Medicare & Medicaid Services(CMS)에 따르면, 2021년 미국의 의료비 지출은 2.7% 증가한 4조 3,000억 달러에 달할 것으로 예상됩니다. 이러한 의료비 지출의 대폭적인 증가는 암 면역 치료제의 발전을 촉진하고 궁극적으로 암 치료 결과와 이러한 혁신적인 치료법에 대한 환자의 접근성을 향상시킬 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • 시장에 대한 COVID-19의 영향

제5장 세계 시장 규모와 성장

  • 세계의 암 면역치료제 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 암 면역치료제 시장 규모 실적과 성장, 2018-2023년
  • 세계의 암 면역치료제 시장 규모와 성장 예측, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 암 면역치료제 시장, 유형별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 단클론항체
  • 면역관문 억제제
  • 면역 시스템 조절인자
  • 암백신
  • 기타
  • 세계의 암 면역치료제 시장, 치료 용도별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 흑색종
  • 폐암
  • 혈액암
  • 신장세포암
  • 전립선암
  • 방광암
  • 기타
  • 세계의 암 면역치료제 시장, 최종사용자별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 병원
  • 클리닉
  • 외래수술센터(ASC)
  • 암연구

제7장 지역 및 국가별 분석

  • 세계의 암 면역치료제 시장, 지역별, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 암 면역치료제 시장, 국가별, 실적과 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

  • 암 면역치료제 시장 경쟁 구도
  • 암 면역치료제 시장 기업 개요
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co.
    • Bristol-Myers Squibb Company
    • Amgen Inc
    • Johnson &Johnson

제31장 기타 주요 기업과 혁신 기업

  • AstraZeneca Plc
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Arlak Biotech
  • Healthkind Labs Pvt. Ltd.
  • SwisscheM Healthcare Pvt.Ltd
  • Apikos Pharma
  • Kolaz biotech
  • CStone Pharma
  • CARsgen Therapeutics
  • JW Therapeutics
  • BeiGene
  • Takeda Pharmaceuticals

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 향후 전망과 잠재성 분석

제36장 부록

LSH 24.03.08

Immuno-oncology drugs constitute a form of therapy or cancer treatment that utilizes drugs to either enhance or suppress the immune system, aiming to fortify the body's defenses against cancer, infections, and other disorders. These drugs leverage chemicals produced naturally by the body or synthesized in a laboratory to reinforce the immune system's capabilities, aiding the body in identifying and eliminating cancer cells.

The primary categories within the immuno-oncology drugs market include monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, cancer vaccines, and others. Monoclonal antibodies are produced through the cloning of a single white blood cell, with each subsequent antibody traceable back to a single parent cell. Various therapeutic applications encompass melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer, and others. The application of immuno-oncology drugs spans sectors such as hospitals, clinics, ambulatory surgical centers, and cancer research institutes.

The immuno-oncology drugs market research report is one of a series of new reports from The Business Research Company that provides immuno-oncology drugs market statistics, including industry global market size, regional shares, competitors with an immuno-oncology drugs market share, detailed immuno-oncology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the immuno-oncology drugs industry. This immuno-oncology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immuno-oncology drugs market size has grown rapidly in recent years. It will grow from $92.78 billion in 2023 to $105.64 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The expansion observed in the historical period can be attributed to the increase in the number of cancer cases, robust economic growth in emerging markets, heightened healthcare expenditure, and a rise in pharmaceutical research and development (R&D) spending. However, the market faced constraints due to factors such as the high cost of immuno-oncology therapies, limited healthcare access, pricing pressures from regulators, elevated R&D costs, and the expiration of patents for certain drugs.

The immuno-oncology drugs market size is expected to see rapid growth in the next few years. It will grow to $175.05 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. The anticipated growth in the forecast period can be attributed to increasing investments in immuno-oncology, a growing emphasis on immunotherapy drugs for cancer treatment, product innovations achieved through strategic collaborations, and the rising geriatric population, which is expected to drive the market. Significant trends in the forecast period include the development of microneedle injector-based drugs to enhance bioavailability and mitigate side effects associated with the subcutaneous route. Companies are advised to consider investing in the development of personalized oncology drugs tailored to specific patient profiles, explore acquisitions to increase market shares and expand product portfolios, focus efforts on the development of next-generation biologics to boost revenue and market share, and prioritize the creation of antibody-drug conjugates for cancer treatment. Additionally, investments in AI solutions to reduce R&D costs and save development time, the adoption of 3D printing devices for testing new oncology drugs, exploration of immune-oncology combination therapies for innovation and category leadership, and the implementation of CAR-T therapies to drive innovation and establish category leadership are recommended strategies.

The growth of the immuno-oncology drugs market is expected to be fueled by the global increase in cancer cases. Notably, the American Cancer Society reported in January 2022 that the US alone is projected to witness 1.9 million new cancer diagnoses and 609,360 cancer-related deaths, highlighting the severity of the issue. The most prevalent types of cancer globally, including lung, prostate, bowel, and female breast cancer, collectively account for 43% of all new cancer cases. As cancer incidence rates rise globally, there is an anticipated surge in demand for immuno-oncology drugs in the coming years.

The expansion of healthcare expenditure is identified as a significant driver for the immuno-oncology drugs market. Healthcare expenditure, denoting the total financial resources allocated by individuals, organizations, or governments for healthcare-related goods and services, is a key determinant in the development, accessibility, and utilization of immuno-oncology drugs. In 2021, U.S. health care spending reached $4.3 trillion, growing by 2.7 percent, according to the Centers for Medicare & Medicaid Services (CMS). This substantial increase in healthcare spending is expected to drive advancements in immuno-oncology drugs, ultimately enhancing cancer treatment outcomes and patient access to these innovative therapies.

Companies operating in the immuno-oncology drugs market are actively engaging in strategic collaborations to foster product innovation. In response to the intensifying competition in this market, companies are not only focusing on developing groundbreaking products but also leveraging partnerships to share expertise and skills. An example of this collaborative trend is the agreement between Boehringer Ingelheim, a Germany-based pharmaceutical company, and OSE Immunotherapeutics, a France-based biotechnology company. This collaboration, announced in September 2021, aims to develop a novel checkpoint inhibitor for treating advanced solid tumors.

Major players in the immuno-oncology drugs market are concentrating on product development to diversify their cancer therapy portfolios. Tebentafusp-TEBN, a novel immuno-oncology drug, is a notable product in this context. It combines a T-cell receptor (TCR) with an anti-CD3 antibody fragment, designed to target and engage T cells with cancer cells, particularly melanoma. Immunocore, a UK-based biotechnology company, received FDA approval for KIMMTRAKR (Tebentafusp-TEBN) in January 2022. This approval marks a significant milestone as KIMMTRAKR is the first FDA-approved treatment for unresectable or metastatic uveal melanoma, showcasing its potential to extend overall survival.

In December 2021, Sanofi S.A., a France-based biopharmaceutical and healthcare company, completed the acquisition of Amunix Pharmaceuticals, Inc., for $1 billion. This strategic move enhances Sanofi's capabilities in developing innovative cancer medicines, particularly in the realm of immuno-oncology. The acquisition positions Sanofi to bring potentially superior and safer treatment candidates to patients by leveraging its expertise and collaborating as a center of excellence, thereby strengthening its oncology pipeline. Amunix Pharmaceuticals, Inc., a US-based biopharmaceutical company, specializes in the discovery and development of novel immuno-oncology drugs.

Major companies operating in the immuno-oncology drugs market report are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc., Johnson & Johnson, AstraZeneca PLC, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd., Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc., Otsuka Pharmaceutical Co, Ltd., Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline PLC, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab

North America was the largest region in the immuno-oncology drugs market in 2023. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the immuno-oncology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The immuno-oncology drugs market consists of sales of bevacizumab, alectinib, ibrutinib, imatinib, and palbociclib. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immuno-Oncology Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immuno-oncology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immuno-oncology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immuno-oncology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Immune Checkpoint Inhibitors; Immune System Modulators; Other Monoclonal Antibodies; Cancer Vaccines; Others
  • 2) By Therapeutic Application: Melanoma; Lung Cancer; Blood Cancer; Renal Cell Carcinoma; Bladder Cancer; Other Therapeutic Application
  • 3) By End-Users: Hospitals; Clinics; Ambulatory Surgical Centers; Others
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co.; Bristol-Myers Squibb Company; Amgen Inc; Johnson & Johnson
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immuno-Oncology Drugs Market Characteristics

3. Immuno-Oncology Drugs Market Trends And Strategies

4. Immuno-Oncology Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Immuno-Oncology Drugs Market Size and Growth

  • 5.1. Global Immuno-Oncology Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Immuno-Oncology Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Immuno-Oncology Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Immuno-Oncology Drugs Market Segmentation

  • 6.1. Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
  • Immune System Modulators
  • Cancer Vaccines
  • Other Types
  • 6.2. Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Melanoma
  • Lung Cancer
  • Blood Cancer
  • Renal Cell Carcinoma
  • Prostate Cancer
  • Bladder Cancer
  • Other Therapeutic Applications
  • 6.3. Global Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Cancer Research Institutes

7. Immuno-Oncology Drugs Market Regional And Country Analysis

  • 7.1. Global Immuno-Oncology Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Immuno-Oncology Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Immuno-Oncology Drugs Market

  • 8.1. Asia-Pacific Immuno-Oncology Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Immuno-Oncology Drugs Market

  • 9.1. China Immuno-Oncology Drugs Market Overview
  • 9.2. China Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Immuno-Oncology Drugs Market

  • 10.1. India Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Immuno-Oncology Drugs Market

  • 11.1. Japan Immuno-Oncology Drugs Market Overview
  • 11.2. Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Immuno-Oncology Drugs Market

  • 12.1. Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Immuno-Oncology Drugs Market

  • 13.1. Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Immuno-Oncology Drugs Market

  • 14.1. South Korea Immuno-Oncology Drugs Market Overview
  • 14.2. South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Immuno-Oncology Drugs Market

  • 15.1. Western Europe Immuno-Oncology Drugs Market Overview
  • 15.2. Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Immuno-Oncology Drugs Market

  • 16.1. UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Immuno-Oncology Drugs Market

  • 17.1. Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Immuno-Oncology Drugs Market

  • 18.1. France Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Immuno-Oncology Drugs Market

  • 19.1. Italy Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Immuno-Oncology Drugs Market

  • 20.1. Spain Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Immuno-Oncology Drugs Market

  • 21.1. Eastern Europe Immuno-Oncology Drugs Market Overview
  • 21.2. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Immuno-Oncology Drugs Market

  • 22.1. Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Immuno-Oncology Drugs Market

  • 23.1. North America Immuno-Oncology Drugs Market Overview
  • 23.2. North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Immuno-Oncology Drugs Market

  • 24.1. USA Immuno-Oncology Drugs Market Overview
  • 24.2. USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Immuno-Oncology Drugs Market

  • 25.1. Canada Immuno-Oncology Drugs Market Overview
  • 25.2. Canada Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Immuno-Oncology Drugs Market

  • 26.1. South America Immuno-Oncology Drugs Market Overview
  • 26.2. South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Immuno-Oncology Drugs Market

  • 27.1. Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Immuno-Oncology Drugs Market

  • 28.1. Middle East Immuno-Oncology Drugs Market Overview
  • 28.2. Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Immuno-Oncology Drugs Market

  • 29.1. Africa Immuno-Oncology Drugs Market Overview
  • 29.2. Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Immuno-Oncology Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Immuno-Oncology Drugs Market Competitive Landscape
  • 30.2. Immuno-Oncology Drugs Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bristol-Myers Squibb Company
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Amgen Inc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Johnson & Johnson
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Immuno-Oncology Drugs Market Other Major And Innovative Companies

  • 31.1. AstraZeneca Plc
  • 31.2. Eli Lilly and Company
  • 31.3. Novartis International AG
  • 31.4. Pfizer Inc.
  • 31.5. Sanofi S.A.
  • 31.6. Arlak Biotech
  • 31.7. Healthkind Labs Pvt. Ltd.
  • 31.8. SwisscheM Healthcare Pvt.Ltd
  • 31.9. Apikos Pharma
  • 31.10. Kolaz biotech
  • 31.11. CStone Pharma
  • 31.12. CARsgen Therapeutics
  • 31.13. JW Therapeutics
  • 31.14. BeiGene
  • 31.15. Takeda Pharmaceuticals

32. Global Immuno-Oncology Drugs Market Competitive Benchmarking

33. Global Immuno-Oncology Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Immuno-Oncology Drugs Market

35. Immuno-Oncology Drugs Market Future Outlook and Potential Analysis

  • 35.1 Immuno-Oncology Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Immuno-Oncology Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Immuno-Oncology Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제